CPI-0209: A study of CPI-0209 in relapsed or refractory diffuse large B-cell and peripheral T-cell lymphomas

This phase 1 and 2 trial is testing the EZH2/1 inhibitor CPI-0209 as monotherapy in adults with advanced lymphomas.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04104776

Trial aim and background  

Evidence is showing that the inhibitor EZH2 is overexpressed in many cancer types including certain lymphomas and has a key role in how they progress. The aim of this trial is to find out more about the EZH2/1 inhibitor CPI-0209 as monotherapy including how safe and well tolerated it is. 

The first phase of the trial is to see what the maximum tolerated dose is, and the second phase will look at how well it works in certain cancer types. This will include patients with diffuse larger b-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) which has failed to respond to (refractory) or returned after (relapsed) one systemic treatment. 

Part of this trial is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter 

Patients with DLBCL or PTCL which has not responded to one systemic treatment may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • Royal United Hospital, Bath
  • University Hospitals of Leicester NHS Trust, Leicester
  • The Christie NHS Foundation Trust, Manchester
  • Royal Marsden Hospital, Sutton
  • Musgrove Park Hospital, Taunton

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.clinicaltrials.gov/study/NCT04104776

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.